Abstract
Based on the strong activity of belinostat, the study synthesized of some cinnamoylhydroxamic acid derivatives with the aim of creating new compounds that have the potential to selectively inhibit HDAC to contribute to cancer treatment. N-hydroxycinnamamide serves as both ZBG and the linker group. The derivatives orient to the HDAC2 and HDAC8 enzymes by molecular docking. Compound 9a (bearing sulfonamide) exhibited as the most potential candidate to inhibit the function of HDAC2 enzyme.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: VNU Journal of Science: Natural Sciences and Technology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
